Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance
نویسندگان
چکیده
منابع مشابه
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.
BACKGROUND High-dose therapy and autologous stem cell transplantation (ASCT) improves outcomes for patients with mantle cell lymphoma (MCL), but relapse ultimately occurs in most patients. Recently presented interim results from a phase III prospective trial suggest maintenance rituximab (MR) after ASCT for MCL improves progression-free survival (PFS). The maturation of these data and any benef...
متن کاملRituximab for Mantle Cell Lymphoma
MCL usually responds to chemotherapy, only to relapse frequently, with a much shorter duration of response, time to progression, and overall survival compared to follicular NHL. The treatment approach for newly diagnosed patients generally depends on whether they are transplant-eligible. Only a small minority of patients achieve sustained remission after first-line therapy, and sequential thera...
متن کاملTemsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.
BACKGROUND Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor with single-agent antitumour activity in patients with mantle cell lymphoma. We therefore tested its efficacy and toxicity in combination with rituximab (an antiCD20 antibody) in patients with relapsed or refractory mantle cell lymphoma. METHODS In a phase 2 study, patients (aged ≥18 years) at 35 centres in the USA we...
متن کاملMaintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.
BACKGROUND There is no standard first line treatment for mantle cell lymphoma. PATIENTS AND METHODS This was a multicenter phase II pilot study of rituximab and modified hyper-fractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (modified R-hyperCVAD) administered every 28 days for four to six cycles followed by rituximab maintenance therapy consisting of four weekly doses ev...
متن کاملFirst-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.
UNLABELLED The prognosis for fit patients with mantle cell lymphoma has improved with intensive strategies. Currently, the role of maintenance/consolidation approaches is being tested as relapses continue to appear. In this trial we evaluated the feasibility, safety and efficacy of rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine followed by consolidation with (90)Y-ibritu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bone Marrow Transplantation
سال: 2011
ISSN: 0268-3369,1476-5365
DOI: 10.1038/bmt.2011.218